Long term follow-up and further molecular and histopathological studies in the LGMD1F sporadic TNPO3-mutated patient | Acta Neuropathologica Communications | Full Text

Long term follow-up and further molecular and histopathological studies in the LGMD1F sporadic TNPO3-mutated patient | Acta Neuropathologica Communications | Full Text



Acta Neuropathologica Communications

Long term follow-up and further molecular and histopathological studies in the LGMD1F sporadic TNPO3-mutated patient

• Sara Gibertini,
• Alessandra Ruggieri,
• Simona Saredi,
• Franco Salerno,
• Flavia Blasevich,
• Laura Napoli,
• Maurizio Moggio,
• Vincenzo Nigro,
• Lucia Morandi,
• Lorenzo Maggi and
• Marina MoraEmail authorView ORCID ID profile

Acta Neuropathologica Communications20186:141

https://doi.org/10.1186/s40478-018-0648-4

©  The Author(s). 2018

• Received: 11 November 2018
• Accepted: 10 December 2018
• Published: 19 December 2018

Keywords

• TNPO3
• Transportin 3
• LGMD1F

Introduction

Limb girdle muscular dystrophies (LGMD) are a large group of muscular disorders, with progressive shoulder and pelvic muscle weakness as the most relevant feature. They are classified as autosomal dominant (LGMD1) and autosomal recessive (LGMD2) forms. Up to now, eight genetically defined LGMD1 subtypes (LGMD1 A-H) have been identified [1, 9].

In 2001, the clinical and morphological phenotype of a novel form of LGMD type 1, affecting 32 subjects in a large Spanish family, was described [5]. According to subsequent molecular studies, the disease was demonstrated to be linked to the novel chromosomal locus 7q32.1–32.2. This genetically distinct form of autosomal dominant-LGMD was classified as LGMD1F [10] (OMIM #608423). Recently, using a whole genome sequencing approach, the causative mutation of the LGMD1F was identified in the termination codon of TNPO3, the gene coding for transportin 3. Molecular results at DNA, RNA and protein levels as well as morphological findings supported the pathogenic role of this mutation in LGMD1F [8]. Investigation by next-generation sequencing in further 4 members of the Spanish family, originating from Italy, confirmed the mutation in TNPO3 [13]. Up to now, beside this Italo-Spanish family, only one sporadic LGMD patient has been identified with a heterozygous point mutation in the TNPO3 gene [13].

In this patient we now report the long term clinical and radiological follow-up, morphological and immunochemical studies on patient muscle biopsy, and molecular studies by Real Time PCR and by cell transfection with the mutant cDNA.